In Situ Construction of Upconverting Nano-Bacteria Biohybrids via Biomimetic Mineralization for Synergistic Antitumor Phototherapy
Source abstract
Abstract
Nano-bacteria biohybrids, which combine the advantages of nanomaterials and bacterial cells, have emerged as innovative platforms for cancer treatment. Integrated with optical nanomaterials, these biohybrids enable effective phototherapy. To overcome the challenge of limited tissue penetration by visible light in phototherapy, upconversion nanoparticles can be used to convert near-infrared (NIR) light into visible light, enabling the treatment of deep-seated tumors. In this study, we present a rapid method to fabricate upconversion nanoparticle-bacteria biohybrids ( E. coli @BiF 3:Yb/Er) via biomimetic mineralization under biocompatible conditions within minutes. Additionally, palladium nanoparticles are co-mineralized, enabling the biohybrids to perform both photodynamic and photothermal therapies under NIR light. When applied to mouse models of melanoma and cervical cancer, these biohybrids target the tumor sites efficiently without causing systemic toxicity. Upon excitation with 980 and 808 nm NIR light, these biohybrids effectively suppressed tumor growth, highlighting their potential as a multifunctional therapeutic strategy for cancer treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Cancer Research and Treatments · Nanoplatforms for cancer theranostics · 3D Printing in Biomedical Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Environmental and Chemical Engineering
Shanghai University
Funding
Innovative Research Team of High-level Local University in Shanghai · National Natural Science Foundation of China · Shenzhen Medical Academy of Research and Translation
References (39)
Show source-provided references
1. 10.1126/science.add966710.1126/science.add9667 ↗
2. 10.1002/advs.20200357210.1002/advs.202003572 ↗
3. 10.1016/j.apsb.2023.11.00710.1016/j.apsb.2023.11.007 ↗
4. 10.1016/j.biomaterials.2021.12112410.1016/j.biomaterials.2021.121124 ↗
5. 10.3389/fimmu.2023.114046310.3389/fimmu.2023.1140463 ↗
6. 10.1073/pnas.220271911910.1073/pnas.2202719119 ↗
7. 10.1073/pnas.040842210210.1073/pnas.0408422102 ↗
8. 10.1016/j.omto.2022.05.00410.1016/j.omto.2022.05.004 ↗
9. 10.1016/j.jconrel.2023.06.00910.1016/j.jconrel.2023.06.009 ↗
10. 10.1016/j.addr.2016.09.00710.1016/j.addr.2016.09.007 ↗
11. 10.1021/acsnano.1c0835010.1021/acsnano.1c08350 ↗
12. 10.1021/acs.nanolett.1c0040810.1021/acs.nanolett.1c00408 ↗
13. 10.1021/acsami.2c0113810.1021/acsami.2c01138 ↗
14. 10.1021/acsnano.1c0612310.1021/acsnano.1c06123 ↗
15. 10.1002/advs.20190135810.1002/advs.201901358 ↗
16. 10.1039/C4CS00158C10.1039/C4CS00158C ↗
17. 10.1016/j.celrep.2021.10969010.1016/j.celrep.2021.109690 ↗
18. 10.1021/acsami.2c1463310.1021/acsami.2c14633 ↗
19. 10.1126/sciadv.adk948510.1126/sciadv.adk9485 ↗
20. 10.1016/j.nantod.2019.02.00910.1016/j.nantod.2019.02.009 ↗
21. 10.1039/C4CS00186A10.1039/C4CS00186A ↗
22. 10.1021/acs.accounts.5b0007810.1021/acs.accounts.5b00078 ↗
23. 10.1016/j.actbio.2020.06.03810.1016/j.actbio.2020.06.038 ↗
24. 10.1002/adhm.20200004610.1002/adhm.202000046 ↗
25. 10.1126/science.aad331710.1126/science.aad3317 ↗
26. 10.1039/C7CC03794E10.1039/C7CC03794E ↗
27. 10.1002/adfm.20190980610.1002/adfm.201909806 ↗
28. 10.1007/s00604-018-2777-710.1007/s00604-018-2777-7 ↗
29. 10.1002/adma.20170050510.1002/adma.201700505 ↗
30. 10.1021/acsanm.0c0040310.1021/acsanm.0c00403 ↗
31. 10.1039/D2CP03982F10.1039/D2CP03982F ↗
32. 10.1016/j.actbio.2024.01.00710.1016/j.actbio.2024.01.007 ↗
33. 10.1039/C9NR09401F10.1039/C9NR09401F ↗
34. 10.1021/acsami.5c0140410.1021/acsami.5c01404 ↗
35. 10.1021/acsnano.3c0089110.1021/acsnano.3c00891 ↗
36. 10.1128/AEM.01390-1210.1128/AEM.01390-12 ↗
37. 10.7150/thno.9809710.7150/thno.98097 ↗
38. 10.1021/acsami.4c1707910.1021/acsami.4c17079 ↗
39. 10.1016/j.biomaterials.2017.10.04810.1016/j.biomaterials.2017.10.048 ↗